This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dendreon: Medicare Coverage Fears Allayed

Updated with new headline, analyst comments

SEATTLE ( TheStreet) -- The U.S. agency in charge of Medicare has scheduled a meeting for Nov. 17 to discuss the use of Dendreon's (DNDN) prostate cancer vaccine Provenge.

The meeting announcement was posted Tuesday on the web site of the Centers for Medicare and Medicaid Services (CMS).

"The Centers for Medicare and Medicaid Services (CMS) has called this meeting to consider the currently available evidence regarding the impact of labeled and unlabeled use of autologous cellular immunotherapy treatment on health outcomes of patients with metastatic prostate cancer," the agency's announcement stated.

The fact that CMS is focusing its attention on which prostate cancer patients to treat with Provenge and will not consider the broader question of whether or not to reimburse at all for the $93,000-per-treatment drug is a positive and should help allay investor concerns.

Deutsche Bank biotech analyst Robyn Karnauskas in a note to clients Tuesday night said she expects CMS will conclude that Provenge coverage should hue closely to the type of prostate cancer patients that were treated in the Provenge clinical trials.

That outcome "will not change street estimates in our view," Karnauskas writes, adding, "These eligibility criteria we expect to be put in place are in-line with those of the IMPACT trial. This is the way that we, and the Street, model Provenge's market opportunity." Karnauskas has a buy rating on Dendreon with a $44 price target.

Dendreon shares rollercoastered in June when CMS announced that it was opening an assessment to determine a national coverage decision of Provenge, which received FDA approval earlier this year as a treatment for advanced prostate cancer.

Since that announcement, Dendreon has indicated that 14 of the 15 regional Medicare carriers are either already reimbursing patients for Provenge or have signaled their intention to do so. Strong demand for Provenge in the form of patients on waiting lists to receive the drug has also been reported by the company.

Dendreon shares closed Tuesday up 15 cents to $35.84 but jumped another 66 cents, or almost 2% to $36.50 once investors became aware of the scheduling of the Medicare meeting.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
DNDN $0.06 -6.02%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs